The Inflation Reduction Act: Implications for Medicare spending and access to biologic therapies for chronic rhinosinusitis with nasal polyposis and asthma.

Autor: Rathi VK; Division of Rhinology and Sinus Surgery, Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA., Soler ZM; Division of Rhinology and Sinus Surgery, Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA., Schlosser RJ; Division of Rhinology and Sinus Surgery, Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.; Department of Surgery, Ralph H. Johnson VA Medical Center, Charleston, South Carolina, USA., Workman AD; Division of Rhinology, Department of Otolaryngology-Head & Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Chapurin N; Department of Otolaryngology-Head & Neck Surgery, University of Florida, Gainesville, Florida, USA., Rowan NR; Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Dusetzina SB; Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
Jazyk: angličtina
Zdroj: International forum of allergy & rhinology [Int Forum Allergy Rhinol] 2024 Jul; Vol. 14 (7), pp. 1261-1265. Date of Electronic Publication: 2024 Mar 11.
DOI: 10.1002/alr.23344
Abstrakt: Key Points: In 2021, Medicare spending on biologics was $926 million in Part B (FFS) and $1.3 billion in Part D (FFS/MA). Between 2017 and 2021, annual Medicare spending on biologics increased by approximately 200%. Between 2023 and 2025, Medicare Part D OOP costs for biologics will decrease by an estimated 50%-60%.
(© 2024 ARS‐AAOA, LLC.)
Databáze: MEDLINE
Externí odkaz: